Hailie inhaler monitoring system maker Adherium has announced the appointment of Tara Creaven-Capasso as VP of Quality, Regulatory and Clinical Affairs. Creaven-Capasso has been a long-time regulatory affairs consultant; earlier in her career, she also held QA positions at several companies, including Xoma and Medtronic. Adherium received 510(k) clearance for its next generation Hailie inhaler sensors in September 2021, and the company recently submitted a 510(k) for a new Hailie sensor designed specifically for use with Ellipta DPIs.
Adherium CEO Rick Legleiter commented, “At this pivotal time in our growth strategy, we are extremely pleased to welcome Tara further strengthening our team. Her commercial pathway experience with the regulatory strategy and clinical trial management along with her excellent relationships and extensive background successfully negotiating with the FDA and other regulatory bodies will drive Adherium’s market expansion forward.”
Creaven-Capasso said, “I have dedicated my career to bringing innovative technologies to market, for the purpose of improving patient’s quality of life, while solving clinical problems. Development of robust regulatory strategies and quality management systems is essential when looking to commercialize and achieve market access of high quality, competitive, and compliant products. I am honored to take on a broader role with the Adherium team to help deliver on its mission. I look forward to applying my expertise in guiding the company as it continues to build on its commercial strategies.”
Adherium also said that the company is recruiting for the Chief Financial Officer position because “Robert Spurr’s interim CFO assignment has concluded.”
Read the Adherium press release.
